← All bills · H.R. 10857 · Introduced Oct 22, 2026
Faster Clinical Trials Act
What it says it's for
To amend the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
Policy area: Health
Latest action (Oct 22, 2026): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sus-Meter · its most off-topic section
23 of 24 sections checked
Zero side quests 🎉
Every section we checked lines up with the bill's stated purpose. It understood the assignment.
All 24 sections
- Not scored
Sec. 1. Short title; table of contents
Standard boilerplate
1.Short title; table of contents (a)Short titleThis Act may be cited as the Faster Clinical Trials Act. (b)Table of contentsThe table of contents for this Act is as follows: Sec. 1. Short title; table of contents. Title I—Embedding Clinical Studies in Routine Health Care Sec. 101. Cures in Care Initiative. Sec. 102. Cures in Care Initiative lead network grant program. Sec. 103. Cures in Care Initiative Collaborative. Sec. 104. Definitions for Cures in Care Initiative and related activities. Sec. 105. Data standards with respect to data sharing. Sec. 106. Clinical trial oversight modernization. Sec. 107. Updates to patient costs and payment for participation in clinical trials. Title…
- On topic
Sec. 101. Cures in Care Initiative
101.Cures in Care Initiative (a)In generalPart J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following: 499B.Cures in Care Initiative establishment (a)Center for Clinical Trial InnovationThe Secretary shall establish the Center for Clinical Trial Innovation (in this section referred to as the Center) within the Center for Drug Evaluation and Research of the Food and Drug Administration to carry out the Initiative established under subsection (b), to be headed by a director. (b)Establishment of Cures in Care Initiative (1)In generalThe Secretary, acting through the Assistant Secretary of Health shall continue a Cures in Care…
- On topic
Sec. 102. Cures in Care Initiative lead network grant program
102.Cures in Care Initiative lead network grant program Part J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following: 499C.Cures in Care Initiative lead network grant program (a) In general Not later than 5 years after the date of enactment of this subsection, the Commissioner of Food and Drugs, in consultation with the Director of the Center for Clinical Trial Innovation, and the Director of the National Institutes of Health, acting through the Center for Advancing Translational Sciences and the Advanced Research Projects Agency–Health, (in this section referred to as the Commissioner and Director) shall make grants to, or enter…
- On topic
Sec. 103. Cures in Care Initiative Collaborative
103.Cures in Care Initiative Collaborative Part J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following: 499D.Cures in Care Initiative Collaborative (a)In generalThe Secretary, acting through the Director of NIH and the Director of the Center for Clinical Trial Innovation, shall establish, through entering into a contract, cooperative agreement, memorandum of understanding, or other mechanism, a public-private partnership, to be known as the Cures in Care Initiative Collaborative (in this section referred to as the Collaborative), to— (1)promote routine point-of-care clinical trials, including the development of novel trial…
- On topic
Sec. 104. Definitions for Cures in Care Initiative and related activities
104.Definitions for Cures in Care Initiative and related activitiesPart J of title IV of the Public Health Service Act (42 U.S.C. 290c et seq.) is amended by adding at the end the following: 499E.Definitions for Cures in Care Initiative and related activitiesIn this part: (1)Clinical investigationThe term clinical investigation has the meaning given such term in section 50.3 of title 21, Code of Federal Regulations (or any successor regulation). (2)Innovative clinical trial methodThe term innovative clinical trial method includes adaptive, decentralized, Bayesian, platform, and external-control trial designs, as such terms are described in guidance issued by the Food and Drug…
- On topic
Sec. 105. Data standards with respect to data sharing
105.Data standards with respect to data sharing (a) In general Not later than 18 months after the date of enactment of this Act, the Administrator of the Centers for Medicare & Medicaid Services, the Commissioner of Food and Drugs, and the National Coordinator for Health Information Technology (in this section referred to as the Administrator) shall establish a list of data standards for the purpose of facilitating the exchange of patient data for routine point-of-care clinical trials and contribution to Federal datasets using established common data models. (b)Required contentsIn establishing the list under subsection (a), the Administrator shall include— (1)the United States Core Data for…
- On topic
Sec. 106. Clinical trial oversight modernization
106.Clinical trial oversight modernization (a)Single IRB requirement for certain clinical investigations (1) In general Subject to paragraph (2), a sponsor of multi-institutional or cooperative clinical investigations of medical products regulated under parts 45 and 56 of title 21, Code of Federal Regulations (or any successor regulations), shall designate a single institutional review board with respect to the review of such investigation. (2)ExceptionIf, in an investigational new drug application or investigational device exemption application, the sponsor described in paragraph (1) demonstrates that an alternative manner of review is necessary and the designation of only one…
- On topic
Sec. 107. Updates to patient costs and payment for participation in clinical trials
107.Updates to patient costs and payment for participation in clinical trials (a)Enabling coverage of patient costs and use of evidence (1)Routine care cost coverage clarification (A)In generalNot later than 18 months after the date of enactment of this Act, the Administrator of the Centers for Medicare & Medicaid Services shall issue guidance, or update the National Coverage Determination for Routine Costs in Clinical Trials, to clarify that a routine point-of-care clinical trial is a qualifying clinical trial, such that coverage is available under the Medicare program under title XVIII of the Social Security Act (42 U.S.C. 1395 et seq.) for routine costs incurred in connection with such…
- On topic
Sec. 201. Modernized evidence generation through new approach methodologies
201.Modernized evidence generation through new approach methodologies (a)Guidance for implementation of new approach methodologies (1) In general Not later than 2 years after the date of enactment of this Act, the Secretary, acting through the Commissioner of Food and Drugs (in this section referred to as the Commissioner), shall issue guidance and evidence frameworks, including through amending existing guidance or frameworks, to facilitate the implementation of new approach methodologies for the purpose of streamlining and accelerating— (A) preclinical pharmacology and toxicology studies; (B) submission of investigational new drug applications; and (C) early clinical phases of drug…
- On topic
Sec. 202. Modernized phase 1 clinical trial oversight
202.Modernized phase 1 clinical trial oversight (a)In generalThe Secretary shall establish an expedited procedure for review and initiation of lower-risk phase 1 trials, including through— (1)issuing guidance, including through amending existing guidance; and (2)establishing the pilot program under subsection (b). (b)Pilot program (1)In generalThe Secretary shall establish a pilot program for the third-party review of lower-risk phase 1 trials. (2)Qualified third parties (A)Consideration as qualified third partyA third party is qualified to review a lower-risk phase 1 trial under the pilot program established under paragraph (1) if such third party— (i)is— (I)an institutional review board;…
- On topic
Sec. 203. Global regulatory alignment to modernize clinical development
203.Global regulatory alignment to modernize clinical development (a)In generalSection 803 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 383) is amended— (1)in subsection (b)— (A)in paragraph (1), by striking , and and inserting a semicolon; (B)by redesignating paragraph (2) as paragraph (4); and (C)by adding after paragraph (1) the following: (2)the standard, entitled Good Clinical Practice, maintained by the International Council for Harmonisation;; and (2)by adding at the end the following: (d) (1)The Secretary shall expand and coordinate efforts, including through enhanced international collaboration, to ensure compliance with the standard, entitled Good Clinical Practice,…
- On topic
Sec. 204. Minimum United States representation in clinical trials
204.Minimum United States representation in clinical trials (a)In generalThe Secretary of Health and Human Services shall require that each pivotal study submitted in support of an application under section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) or section 351(a) of the Public Health Service Act (42 U.S.C. 262(a)) meet the requirements of subsection (b). (b)U.S. participationA pivotal study contained in an application under section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) or section 351(a) of the Public Health Service Act (42 U.S.C. 262(a))— (1)may not be based solely on foreign clinical data; (2)shall include patients enrolled at…
- On topic
Sec. 205. Food and Drug Administration Rare Disease Innovation Hub
205.Food and Drug Administration Rare Disease Innovation Hub The Federal Food, Drug, and Cosmetic Act is amended by adding after section 1014 (21 U.S.C. 360ff–1) the following: 1014A.Food and Drug Administration Rare Disease Innovation Hub (a)Food and Drug Administration Rare Disease Innovation HubThe Secretary shall establish the Food and Drug Administration Rare Disease Innovation Hub (in this section referred to as the Hub) as an Intercenter Institute described in section 1014 to— (1)advance regulatory science for a rare disease or condition; (2)provide technical assistance to review teams assessing rare disease medical products to ensure reviewer consistency and documentation of…
- On topic
Sec. 301. Resolving clinical holds and improving clinical trial efficiency
301.Resolving clinical holds and improving clinical trial efficiency (a)In generalFor purposes of improving the efficiency and integrity of clinical investigations, the Secretary shall address any root cause of a clinical hold imposed under section 312.42 of title 21, Code of Federal Regulations (or any successor regulation), or the disapproval or withdrawal of approval of an investigational device exemption under section 812.30 of such title (or any successor regulation), including— (1)identifying common sources of noncompliance with such regulations and common causes of clinical holds and development delays, with a focus on first-time sponsors of a clinical trial and…
- On topic
Sec. 302. Mutual recognition of GMP standards
302.Mutual recognition of GMP standards (a)Recognition of foreign government inspectionsSection 809 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384e) is amended— (1)in subsection (a)— (A)in paragraph (2), by striking and at the end; (B)in paragraph (3), by striking the period at the end and inserting ; and; and (C)by inserting after paragraph (3) the following: (4)shall implement a procedure for exchanging inspection reports with a foreign government or an agency of a foreign government that the Secretary has entered into an arrangement or agreement with under this section to avoid duplicating an inspection in which a foreign establishment registered under section 510 was found…
- On topic
Sec. 303. Pathway for competitive generic therapies
303.Pathway for competitive generic therapies (a)ReviewThe Secretary shall review and provide recommendations to improve the pathway for competitive generic therapies established pursuant to section 506H of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356h) no later than 12 months after the date of the enactment of this Act. (b)ImprovementFollowing the review under paragraph (1), the Secretary shall— (1)report the review, its findings, and any recommendations to committees of jurisdiction within 12 months of the date of the enactment of this Act; and (2)not later than 6 months after transmitting the review to Congress, begin implementing the recommendations. (c)CollaborationIn…
- On topic
Sec. 304. Biosimilar biological products
304.Biosimilar biological products (a)In generalSection 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) is amended— (1)in the subsection heading, by striking or interchangeable; (2)in paragraph (2)— (A)by striking subparagraph (B); (B)by redesignating clauses (ii) and (iii) of subparagraph (A) as subparagraphs (B) and (C), respectively, and adjusting the margins accordingly; (C)in subparagraph (A)— (i)in clause (i), by redesignating subclauses (I) through (V) as clauses (i) through (v), respectively, and adjusting the margins accordingly; (ii)in clause (i), as so redesignated by clause (i) of this subparagraph, by redesignating items (aa) through (cc) as subclauses (I) through…
- On topic
Sec. 305. Certification of patent information in certain applications for biological products
305.Certification of patent information in certain applications for biological productsSection 351 of the Public Health Service Act (42 U.S.C. 262) is amended by adding at the end the following: (o)Certification of patent information in certain applications (1)In generalAn application submitted under this section for a biological product that includes a full report of a covered investigation shall also include— (A)a certification, in the opinion of the applicant and to the best of their knowledge, with respect to each covered patent— (i)that such patent information has not been filed; (ii)that such patent has expired; (iii)of the date on which such patent will expire; or (iv)that such…
- On topic
Sec. 306. GAO report
306.GAO reportNot later than 3 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to Congress a report evaluating— (1)any progress in implementing section 301 during the period covered by the report; (2)dissemination by the Food and Drug Administration of resources related to developing a drug; (3)implementation by the Secretary of pilot programs using fees made available pursuant to subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379f et seq.), such as the Split Real Time Application Review pilot program, the Model-Informed Drug Development Paired Meeting Program, and the Chemistry, Manufacturing, and…
- On topic
Sec. 307. Definitions
307.DefinitionsIn this Act: (1)Clinical investigationThe term clinical investigation has the meaning given such term in section 50.3 of title 21, Code of Federal Regulations (or any successor regulation). (2)DepartmentThe term Department means the Department of Health and Human Services. (3)Good clinical practiceThe term good clinical practice means the standard, entitled Good Clinical Practice, maintained by the International Council for Harmonisation and implemented by the Secretary. (4) Institutional review board The term institutional review board has the meaning given such term in section 56.102 of title 21, Code of Federal Regulations (or any successor regulation). (5) Investigational…
- On topic
Sec. 401. Findings and purpose
401.Findings and purpose (a)FindingsCongress finds the following: (1)Advances in molecular oncology have enabled the identification of specific genetic alterations that drive certain cancers, enabling the development of targeted therapies with high efficacy in defined patient populations. (2)Approved oncology drug labels frequently reflect clinical trial populations that predate the routine use of genomic profiling and may not adequately reflect current scientific understanding of patient subpopulations for whom a given therapy is inappropriate. (3)Outdated labeling can contribute to suboptimal treatment sequencing, unnecessary toxicity, and foregone opportunity for patients to receive a…
- On topic
Sec. 402. Oncology center of excellence
402.Oncology center of excellence (a)In generalThe Secretary shall establish the Food and Drug Administration Oncology Center of Excellence as an Intercenter Institute described in section 1014 to promote development and facilitate the review of medical products intended to diagnose and treat oncologic and hematologic malignancies, including— (1) cancers in infants, children, and adolescents; and (2)rare cancers. (b)ActivitiesIn addition to the activities of an Intercenter Institute described in section 1014, the Oncology Center of Excellence shall— (1)sponsor or conduct projects to advance the development and regulation of medical products for patients with cancer, including— (A)Project…
- On topic
Sec. 403. Labeling revisions for genomic exclusions in oncology drugs
403.Labeling revisions for genomic exclusions in oncology drugs (a) In general Not later than 12 months after the date of enactment of this Act, the Secretary shall establish, acting through the Food and Drug Administration Oncology Center of Excellence (hereinafter referred to as the Center), a program to assess information that may inform updates to the labeling of approved oncology drugs to incorporate genomic exclusion criteria (hereinafter referred to as the Program). (b)DutiesIn carrying out the Program, the Center shall— (1) identify oncology drugs approved under 505(b) or 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b) or (j)), or licensed under section 351 of…
- Judge unsure
Sec. 501. Establishment of the American Frontier Biobank
501.Establishment of the American Frontier Biobank (a)In generalPart A of title IV of the Public Health Service Act (42 U.S.C. 281et seq.) is amended by adding at the end following: 404P.American frontier biobank (a)In generalPursuant to section 498E, the Director of NIH shall carry out a program to be known as the American Frontier Biobank Program (referred to in this section as the Biobank Program), which shall expand upon the work of the All of Us Research Program. (b)TransitionNot later than 6 months after the date of the enactment of this section, the Director of NIH shall— (1)transfer to the Biobank Program, the authorities (including all budget authorities, available appropriations,…
Checked Nov 15, 2026 with Jev.